Background The role of breast conserving surgery with radiotherapy is well established and has become a widely used procedure in breast cancer. Patient selection, a multidisciplinary approach, and expert surgical technique are important factors to avoid locoregional recurrence. The aim of this study was to analyse the outcomes of patients treated with breast conserving surgery in stage I-II breast cancer.
Introduction
Breast conserving surgery (BCS) has become an alternative surgical procedure used primarily for early stage breast cancer. In the early 1980s, the maximum acceptable tumour size for BCS was 2 cm, and the BCS procedure consisted of a quadrantectomy. In addition, it was generally accepted that BCS was not appropriate for patients with clinically positive lymph nodes. However with advances in radiotherapy and surgical techniques, such as lumpectomy and local excision, BCS can now be performed for larger tumours with more acceptable cosmetic results; lymph node status is no longer considered a contraindication for BCS, since an axillary dissection is performed with an extra incision in nearly all patients. Currently, the most important criterion for BCS is the tumour/breast ratio.
In department of surgery of Ankara Oncology Training and Research Hospital, BCS has been used since 1995 as an alternative to modifi ed radical mastectomy (MRM) in appropriate, selected patients. The aim of this study was to analyse the outcomes of patients treated with BCS in clinical stage I-II breast cancer.
Patients and methods
In this retrospective study breast cancer patients who underwent BCS between February 1995 and December 2005 were enrolled. During this period 144 BCS procedures were performed in 141 patients (3 patients had bilateral malignancies) out of a total of 511 cases with clinical stage I and II breast carcinoma. During the study period it was our department policy to do BCS in patients with T1 and T2 tumours depending on the tumour/breast ratio. BCS was not carried out in multicentric tumours. Re-excision was routine when the margins are very close or positive, and, if suffi cient margins cannot be achieved, then a simple mastectomy was performed. Of the 144, 14 required E. Erdem . H. Alagol Department of 5th General Surgery, Ankara Oncology Training and Research hospital 13th Street, Demetevler, Ankara, Turkey E. Erdem ( ) E-mail: er2dem@gmail.com re-excision because of positive or close margins; 5 of these achieved negative margins, while the other 9 underwent simple mastectomy. Therefore, a total of 135 breast carcinoma cases treated with BCS were followed until April 2008. The BCS consisted of a lumpectomy, a wide excision, or a quadrantectomy combined with level-III axillary lymph node clearance and external beam radiation therapy. Surgical margins <1 mm were considered to be positive and <3 mm were considered to be close margins according to the results of pathological examination. Extent of surgical margins, intraoperative frozen/imprint cytology was used if only there was a doubt about adequacy of margins in time of surgery; instead in routine procedure paraffi n wax results were waited. Level-III axillary dissections were performed in all but 9 patients (93.3%) (1 had severe cardiac failure, 4 were very old patients who could not tolerate general anaesthesia, and 4 had in situ carcinoma with microcalcifi cation on mammography and were treated with stereotactic wide excision). Although these 9 patients had no palpable axillary lymph nodes, they were considered as NX. All but 8 (1 patient had LCIS in which radiotherapy was not indicated, 7 patients with cardiac problems in which radiotherapy was contraindicated that 5 of them also could not get general anaesthesia and were not performed axillary dissection as well) of the patients (94%) were treated with radiotherapy to the breast at a dose of 50 Gy. plus a boost of 5-10 Gy; in 2-3 months after surgery. Thirteen of them (9.6%) also received radiotherapy to the axillary region due to the presence of N2 or N3 axillary stages. Adjuvant systemic chemotherapy was given to 96 patients (71%) that had axillary lymph node involvement or were considered to be at high risk for metastasis; adjuvant hormone therapy was given to 90 patients (66.6%) based on their receptor status. Adjuvant therapy has been performed based on the recommendation of the St. Gallen International Conference with the treatment of anthracycline-based regimens (4-6 cycles of CAF or CEF therapy: 600 mg/m 2 of cyclophosphamide, 60 mg/m 2 of adriamicin or 60-75 mg/m 2 of epirubicin and 600 mg/m 2 of 5-fl ourourasil), only 4 patients before 1996 were given 6 cycles of CMF: 600 mg/m 2 of cyclophosphamide, 40 mg/m 2 of methotrexate and 600 mg/m 2 of 5-fl ourourasil. In adjuvant hormone therapy, tamoxifene 20 mg/day has been used for 5 years. Recently aromatase inhibitors have also been used in postmenopausal patients, in terms of prolonged or switched therapy. Information was collected concerning age, menopausal status, surgical margins, tumour size, lymph node involvement, hormone receptors, tumour differentiation, p53 status and HER-2/neu status. P53 estimation was done routinely between 2001-2004 years, but it was not in practice earlier.
After completing radiotherapy and chemotherapy, the patients were followed clinically in every 3 months for the fi rst 2 years, then every 6 months for the next 3 years and yearly thereafter. Radiological examinations were also performed in every 6-12 months.
The statistical analysis included Kaplan-Meier survival analysis for disease-free (DFS) and overall survivals (OS), and Cox regression analyses to asses each prognostic factor separately using SPSS 10.0 for windows. A p < 0.05 was accepted as signifi cant.
Results
Of the 511 stage I-II breast carcinoma patients, 135 BCS procedures were performed in 132 patients (26.4%) (3 had bilateral carcinoma). The cosmetic results are all good or at least in acceptable condition. The histopathological diagnoses were: invasive ductal carcinoma in 100; lobular carcinoma in 5; mixed lobular + invasive ductal carcinoma in 2; medullary carcinoma in 4; mucinous carcinoma in 5; tubular carcinoma in 3; papillary carcinoma in 2; columnar carcinoma in 1; lobular carcinoma in situ in 1; and ductal carcinoma in situ in 12. The median age at the time of surgery was 49.52 (range, 22-89) years, and the median follow-up was 54 (range, 15-120) months. The patients' characteristics are listed in Table 1 . On histopathology, more than 4 positive axillary lymph nodes were found in 6 cases (N2), and a positive infraclavicular lymph node was found in 3 cases (N3). During follow-up, 5 patients (3.7%) developed locoregional recurrence (LR), and 15 patients experienced a distant metastasis (one of these also had a LR). The 5-year DFS and OS rates were 84% and 90%, respectively (Figs.  1 a, b, c) . No signifi cant predictive factor for LR could be found. While young age, axillary lymph node metastasis, and ER negative status were positive predictive factors for OS, axillary lymph node metastasis and ER negative status were positive predictive factors for DFS (Table 2) .
Discussion
BCS has become the standard treatment for early breast cancer. In various reports, the rate of performing BCS in early breast cancer varies from 10-45% [1, 2]. In our study, the BCS performing rate was 26.4% and this rate has a trend to increase over time, as it was approximately 16.5% before 2000 and 34% after 2000.
BCS was fi rst performed in the 1980s, but the LR rates were rather high (30-40%) [3, 4] . However, the standard use of radiotherapy after BCS has decreased the LR rates to < 10% [5] [6] [7] [8] [9] . Initially, only T1 tumours were selected for BCS, and the acceptable BCS procedure was quadrantectomy, which was defi ned as the excision of the whole quadrant of the breast tissue in which the tumour was found. Later, with increased technical expertise and a multidisciplinary approach, larger tumours began to be treated more conservatively, with lumpectomy and wide excision of the tumour, so that more cosmetic results could be achieved with similar DFS and LR rates [10] . The two most contro-
